Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Ann Plast Surg. 2016 Aug;77(2):217–222. doi: 10.1097/SAP.0000000000000584

TABLE 3.

Outcomes and Complications Stratified by Treatment Cohort

Combined Cohort (n = 11) Surgical Cohort (n = 10) P
Outcomes
 Local recurrence (%) 4 (19) 10 (38.5) <0.01
 Location of recurrence
  Axilla 1 3
  Inguinal fold 0 2
  Groin/genital/perinea 3 3
  Breast 0 2
 Time to recurrence, from closure, mo
  Mean (range) 18.5 (4–30)        6 (1.5–15) <0.001
 Time to recurrence, from cessation of biologics, mo
  Mean (range)    10.5 (2.5–15)* N/A
 Disease progression/development of new lesions 2 (18) 5 (50) <0.001
 Time to progression, from closure, mo
  Mean (range)    18 (16–20)     8.5 (4–10.5) <0.05
  Time to progression, from cessation of biologics, mo
  Mean (range) 10.5 (9–12) N/A
Complications
  Incisional wound dehiscence 0 1
  Surgical-site infection 0 2
  Delayed wound healing 2 0
  Adverse events related to biologic therapy 0 N/A
*

Recurrence occurred in 1 patient after 4 months of active treatment with infliximab. N/A, Not Applicable.

HHS Vulnerability Disclosure